"Centre régional de référence en cancérologie, le Centre Eugène Marquis est un établissement privé d'intérêt collectif (ESPIC) à but non lucratif. Seul établissement de santé en Bretagne exclusivement dédié à la lutte contre le cancer, il fait partie du groupe UNICANCER réunissant les 18 Centres de Lutte Contre le Cancer de France. Le Centre Eugène Marquis est un lieu d'expertise, de savoirs faire, d'écoute et d'attention. Le patient est au cœur de notre métier. Tout au long du parcours de soin, des professionnels experts en cancérologie accompagnent, écoutent et mettent en œuvre une médecine personnalisée. Les médecins bénéficient d'un plateau technique performant et innovant avec un même objectif : un égal accès à des soins de qualité p"

During the past decade, Centre Eugene Marquis; Service d'oncologie conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 5 clinical trials were completed, i.e. on average, 35.7% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 4 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Eugene Marquis; Service d'oncologie" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Institut de Recherches Internationales Servier" with 2 trials sponsored, "SciClone Pharmaceuticals" with 1 trials sponsored, "UNICANCER" with 1 trials sponsored and "University Hospital, Bordeaux" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Eugene Marquis; Service d'oncologie" #1 collaborator was "ADIR, a Servier Group company" with 2 trials as a collaborator, "Foundation Medicine, Inc." with 1 trials as a collaborator, "Institut d'Enseignement à Distance,University Paris - 8" with 1 trials as a collaborator, "Institut national de la santé et de la recherche médicale, CIC 1415, TOURS" with 1 trials as a collaborator and "Institut national de la santé et de la recherche médicale, U930,TOURS" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Centre Eugene Marquis; Service d'oncologie" are "Melanoma" (2 trials), "Metastatic Colorectal Cancer" (2 trials), "Triple-Negative Breast Cancer" (2 trials), "Advanced BRAFV600 Wild-type Melanoma" (1 trials) and "Breast Cancer" (1 trials). Many other conditions were trialed in "Centre Eugene Marquis; Service d'oncologie" in a lesser frequency.

Most popular intervention types in "Centre Eugene Marquis; Service d'oncologie" are "Drug" (15 trials), "Behavioral" (1 trials), "Combination Product" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (5 trials), "Cobimetinib" (4 trials), "Paclitaxel" (4 trials), "Vemurafenib" (3 trials) and "Atezolizumab Placebo" (2 trials). Other intervention names were less common.

The vast majority of trials in "Centre Eugene Marquis; Service d'oncologie" are 16 trials for "All" genders.

Currently, there are NaN active trials in "Centre Eugene Marquis; Service d'oncologie". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Centre Eugene Marquis; Service d'oncologie, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Eugene Marquis; Service d'oncologie, 2 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".